School of Life Science, Lanzhou University, Tianshui South Road No. 222, Chengguan District, Lanzhou 730030, People's Republic of China.
Med Oncol. 2013 Mar;30(1):452. doi: 10.1007/s12032-012-0452-0. Epub 2013 Jan 10.
Recent studies have shown that microRNAs can be stably detected in human plasma and have the potential as non-invasive biomarkers for the diagnosis of cancers. This study evaluates the potential application of plasma microRNAs for the early detection of gastric cancer (GC). We first measured the plasma expression levels of 15 selected microRNAs (miR-1, -106a, -106b, -17-5p, -20a, -21, -221, -27a, -34, -376c, -378, -423-5p, -451, -486, -744) in 30 GC patients and 30 age- and gender-matched healthy controls and then validated those microRNAs that differentiating GC and controls in another 60 GC patients and 60 matched controls using quantitative reverse transcription-polymerase chain reaction. The areas under the receiver operating characteristic (ROC) curves were used to test the sensitivity and specificity of GC diagnosis using these identified plasma microRNAs. Three plasma microRNAs, miR-106b, miR-20a, and miR-221, were significantly elevated in GC patients than in healthy controls (P < 0.05). Furthermore, the areas under the ROC curves using miR-106b, miR-20a, and miR-221 for GC diagnosis were 0.7733 (95 % CI, 0.7758-0.8409), 0.8593 (95 % CI, 0.8046-0.9139), and 0.7960 (95 % CI, 0.7256-0.8664), respectively. Furthermore, these three microRNAs had a statistically significant elevation in GC patients compared with healthy controls at each of the four stages. However, there were no significant differences in the plasma levels of the three microRNAs among the four TNM stages (P > 0.05). Plasma miR-106b, miR-20a, and miR-221 have the potential as novel, non-invasive biomarkers for the early detection of GC.
最近的研究表明，microRNAs 可以在人类血浆中稳定检测到，并且具有作为癌症诊断的非侵入性生物标志物的潜力。本研究评估了血浆 microRNAs 在早期胃癌 (GC) 检测中的潜在应用。我们首先测量了 30 例 GC 患者和 30 例年龄和性别匹配的健康对照者血浆中 15 种选定的 microRNAs（miR-1、-106a、-106b、-17-5p、-20a、-21、-221、-27a、-34、-376c、-378、-423-5p、-451、-486、-744）的表达水平，然后使用定量逆转录-聚合酶链反应在另外 60 例 GC 患者和 60 例匹配对照者中验证了这些区分 GC 和对照者的 microRNAs。使用这些鉴定的血浆 microRNAs 检测 GC 诊断的受试者工作特征 (ROC) 曲线下面积用于测试 GC 诊断的灵敏度和特异性。与健康对照者相比，GC 患者的三种血浆 microRNAs（miR-106b、miR-20a 和 miR-221）显著升高（P < 0.05）。此外，使用 miR-106b、miR-20a 和 miR-221 进行 GC 诊断的 ROC 曲线下面积分别为 0.7733（95 % CI，0.7758-0.8409）、0.8593（95 % CI，0.8046-0.9139）和 0.7960（95 % CI，0.7256-0.8664）。此外，与健康对照者相比，这三种 microRNAs 在 GC 患者的四个分期中均有统计学意义的升高。然而，在四个 TNM 分期中，三种 microRNAs 的血浆水平没有显著差异（P > 0.05）。血浆 miR-106b、miR-20a 和 miR-221 具有作为早期检测 GC 的新型非侵入性生物标志物的潜力。
